For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program.

In this market, the founders who succeed are generally the ones anchored by a strong “why,” a deep sense of humility, and a willingness to take their medicine when reality demands it.

President Donald Trump issued an EO directing a government-wide response to enhance oversight of proxy advisory firms.

The venture market in Q3 2025 resists simple characterization. Secondary market transaction volume remained muted, yet premium pricing rose to 38% of deals.

Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging.

What do life sciences companies need to know about capital markets heading into 2026?

Congress is inching closer to passing the BIOSECURE Act and imposing restrictions on federal agencies and grant recipients related to biotechnology companies of concern.

Q3 2025 confirmed what many venture observers suspected: Startups deploying or developing AI technologies continue to command higher valuations than their non-AI peers.

In Q3 2025, venture capital activity revealed a telling split in the fundraising landscape.

On November 18, 2025, the California Air Resources Board (CARB) convened its third virtual public workshop to discuss implementation of California’s climate disclosure laws, including greenhouse gas (GHG) emissions reporting under Senate Bill 253 (SB 253) and climate-related financial risk reporting under Senate Bill 261 (SB 261).